New anti-telomere strategies represent important goals for the development of selective cancer therapies. In this study, we reported that uncapped telomeres, resulting from pharmacological stabilization of quadruplex DNA by RHPS4 (3,11-difluoro-6,8,13-trimethyl-8H-quino [4,3,2-kl]acridinium methosulfate), trigger specific recruitment and activation of poly-adenosine diphosphate (ADP) ribose polymerase I (PARP1) at the telomeres, forming several ADP-ribose polymers that co-localize with the telomeric repeat binding factor 1 protein and are inhibited by selective PARP(s) inhibitors or PARP1-specific small interfering RNAs. The knockdown of PARP1 prevents repairing of RHPS4-induced telomere DNA breaks, leading to increases in chromosome abnormalities and eventually to the inhibition of tumor cell growth both in vitro and in xenografts. More interestingly, the integration of a TOPO1 inhibitor on the combination treatment proved to have a high therapeutic efficacy ensuing a complete regression of the tumor as well as a significant increase in overall survival and cure of mice even when treatments started at a very late stage of tumor growth. Overall, this work reveals the unexplored link between the PARP1 and G-quadruplex ligands and demonstrates the excellent efficacy of a multicomponent strategy based on the use of PARP inhibitors in telomere-based therapy.
Introduction
Telomeres are the structures at the end of eukaryotic linear chromosomes. Human telomeres consist of double stranded tandem repeats of the hexanucleotide sequence TTAGGG except for the terminal 3 0 G-rich overhang (Makarov et al., 1997; Wright et al., 1997) . Telomeres can fold into t-loops that may result from the invasion of the 3 0 overhang into duplex DNA (Griffith et al., 1999) or into G-quadruplex (G4) DNA, an unusual DNA conformation based on guanine quartets (Oganesian and Bryan, 2007) . Mammalian telomeres are associated with telomeric proteins or shelterin, forming a complex that functions to protect the ends of DNA from degradation and fusion, thus playing an essential role in controlling genomic stability (de Lange, 2005) . Uncapped telomeres, resulting from either loss of function of telomere-binding proteins or loss of telomeric DNA repeats, directly associate with many DNA damage response proteins and induce a response similar to that observed for DNA breaks (d'Adda di Fagagna et al., 2003; Takai et al., 2003) . A wealth of published works revealed that uncapped telomeres can also be obtained by pharmacological G4 stabilization (Kelland, 2007) . RHPS4 (3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl] acridinium methosulfate) is one of the most effective G4 ligands showing a high selectivity for quadruplex DNA structure (Gavathiotis et al., 2003) . We revealed that this agent, by stabilizing G4 DNA at telomeres, impairs fork progression and/or telomere processing, resulting in telomere dysfunction and activation of an ATR-dependent ATM pathway (Rizzo et al., 2009) . Interestingly, in view of clinical application, RHPS4 is active in vivo as a single agent with a good toxicological profile and potentiates the antitumoral efficacy of TOPOI inhibitors in preclinical models of solid tumors (Salvati et al., 2007; Leonetti et al., 2008) .
The poly-adenosine diphosphate (ADP) ribose polymerase (PARP) family consists of a complex number of enzymes that catalyze the poly-ADP ribosylation, a post-translational modification of proteins Burkle, 2005) . Using NAD þ as a substrate, PARPs synthesize ADP-ribose polymers (PARs) that target themselves or other acceptor proteins. This reaction is reversible and the poly(ADP-ribose) glycohydrolase is the PARP's enzymatic counterpart catalyzing PAR catabolism (Burkle, 2005; Gagne´et al., 2006) . Several of the PARP family proteins may be associated with telomeres. Tankyrases 1 and 2, as well as PARP1 and 2, can directly bind to and poly-ADP ribosylate the telomeric repeat binding factors 1 (TRF1) and 2 (TRF2) and affect their association to telomeric DNA, acting as positive regulators for telomere elongation (Smith and de Lange, 1999; Kaminker et al., 2001; Cook et al., 2002; Rippmann et al., 2002) . In addition, upon DNA damage, PARP1 may be recruited to the damaged telomeres, helping to protect telomeres against chromosome end-to-end fusions and genomic instability (Gomez et al., 2006) . PARP1, the founding member of the PARP family, and PARP2 have long been studied as DNA damage responsive enzymes required for maintaining genomic integrity (Ame´et al., 1999) . The intervention of PARP1 and PARP2 takes place early in the steps of the DNA repair process, as these enzymes bind to and are activated by DNA nicks (Pleschke et al., 2000) . Upon poly-ADP ribosylation, PARPs recruit to the damaged site components of BER and NER machineries (Schreiber et al., 2002; Malanga and Althaus, 2005) . Therefore, inhibition of PARP activity would prevent recruitment of repair enzymes to DNA breaks, hampering strand rejoining and consequent generation of permanent single/double-strand breaks, which in turn triggers cell death.
Because of their involvement in repairing of DNA damage, PARP inhibitors are under investigation as chemo-and radio-sensitizers for cancer treatment (Lord and Ashworth, 2008) . The inhibition of PARPs potentiates the activity of DNA-damaging agents such as alkylators, platinums, topoisomerase inhibitors and radiation in in vitro and in vivo models (Tentori and Graziani, 2005; Plummer and Calvert, 2007) . In addition, tumors with DNA repair defects, such as those arising from patients with BRCA mutations, are more sensitive to PARP inhibition, suggesting that PARP inhibitors may be particularly useful for the treatment of cancer with BRCA mutations (Farmer et al., 2005) . On the basis of the promising data on preclinical models, different companies have now initiated oncology clinical trials with PARP inhibitors, ranging in stages from phase 0 to phase 2 (Ratnam and Low, 2007) .
The objective of this work was to study the involvement of PARPs during telomere damages aiming to identify compelling molecules that may have a synergistic effect in the response of tumors to telomere-based therapy.
Results
PARP1 localizes at telomeres, preferentially in cells exposed to the G4-interactive molecule RHPS4 Poly-ADP ribosylation is one of the earliest cellular responses to DNA damage. To test for a possible association between poly-ADP ribosylation and telomere damage, we examined and compared the presence of PARs of untreated cells versus cells exposed to different telomere damage inducers. Telomere uncapping was triggered in BJ-HELT cells by reducing the expression of the telomeric proteins TRF2 and POT1 and by treating the cells with the selective G4 ligand RHPS4 (Salvati et al., 2007, Supplementary Figure 1) . Cells were also exposed to camptothecin (CPT), a specific TOPO1 inhibitor causing DNA damage, including at the telomere level, by interfering with telomere replication (Sugimura et al., 2008) , and to ionizing radiation generating non-specific DNA damage measured by gH2AX foci formation co-localizing with TRF1 ( Supplementary Figure 1) . In agreement with previous studies (Lindahl et al., 1995) , the poly-ADP ribosylation level had greatly increased in cells exposed to CPT and ionizing radiation (Figures 1a and b) . Interestingly, PARs were also detected in cells treated with the telomere-damaging agent RHPS4 (Figures 1a-c and Supplementary Figure 2 ) and they are strictly dependent on S-phase (Supplementary Figure 3) as a result of the alteration in telomere replication (Rizzo et al., 2009 ). More importantly, most of the PAR spots co-localized with the telomeric marker TRF1 in RHPS4 cells (Figure 1d ), suggesting that poly-ADP ribosylation is activated as a consequence of telomere damage. The increased PAR level upon RHPS4 is PARPdependent, because the PARP inhibitor NU1025 led to the disappearance of poly-ADP ribosylated proteins (Figures 1a-c and Supplementary Figure 2) . The activation of PARP(s) upon RHPS4 treatment was further confirmed by a time-dependent activation of PARP activity, leading to an increase of about 50%, 24 h post treatment (Figure 1e ). These results demonstrate that RHPS4 specifically activates PARP at the telomeres. It is worth noting that an augmentation of the level of PAR was not detected in TRF2-or POT1-compromised cells (Figures 1a and b ; Supplementary  Figure 4) , showing that telomere de-protection per se is not sufficient to trigger a marked increase in PARP activation. Overall, these results reveal that RHPS4 triggers a specific telomere damage leading to PARP activation.
Next, we examined whether PARP1 and PARP2, the two solely described DNA damage-dependent PARPs, are recruited to telomeres in cells treated with RHPS4. The PARP2 staining pattern did not seem to change upon RHPS4 treatment and did not show any clear association with TRF1 ( Figure 2a, upper panels) . In contrast, we observed an increased number of PARP1/ TRF1 foci in RHPS4-treated cells (Figure 2a , lower panels). The quantitative analysis revealed that treatment with RHPS4 significantly (Pp0.01) increased the percentage of cells with more than four PARP1/TRF1 associations ( Figure 2b ) and the number of PARP1/ TRF1 co-localizing spots (Figure 2c ). We concluded that PARP1 is recruited to telomeres upon RHPS4 treatment.
To establish further involvement of PARP(s) upon RHPS4-induced telomere damage, the expression of PARP1 and PARP2 was reduced by the transfection of PARP(s)-specific siRNA. Compared with untreated cells or cells transfected with the negative control siGFP, RHPS4-induced poly-ADP ribosylation level decreased in PARP1-compromised cells (Figures 2d-f) . On the contrary, the number of PAR-positive cells as well as the average number of PAR/TRF1 signals did not change upon PARP2 knockdown (Figures 2d-f) . These results indicate that PARP1, but not PARP2, is specifically activated at telomeres of RHPS4-treated cells. Figure 1 Poly-ADP ribosylation occurs at telomeres, preferentially in cells exposed to the G4-interactive molecule RHPS4. BJ-EHLT fibroblasts were exposed to 0.5 mM RHPS4 for 24 h in the presence or absence of NU1025 PARP inhibitor. Cells were also exposed to 1 mM CPT for 2 h and 5 Gy ionizing radiation and the analysis was performed 12 h after the end of treatment. Cells were transfected with 100 nM of siTRF2 or siPOT1 for 48 h. siGFP was used as negative control of transfection and the results are superimposable to that of untreated cells. 
PARP is involved in the recognition and repair of RHPS4-induced telomere damage
We next evaluated the consequences of PARP inhibition in RHPS4-treated cells by using both PARP1-specific interference RNA and GPI 15427 (GPI), a wellestablished PARP inhibitor already characterized by our group and the analog (GPI 21016) of which is now in clinical trial (Tentori et al., 2006; Ratnam and Low, 2007) . The deconvolution analysis, used to examine the formation of telomere dysfunction induced foci, revealed that either siPARP1 or GPI alone did not induce damage (Figures 3a-c) . Alternatively, although treatment with RHPS4 per se induced telomere damage in about 45% of cells, the percentage of telomere dysfunction induced-positive cells and, more markedly, the average number of telomere dysfunction induced foci per nucleus was further enhanced when PARP1 is inhibited (Figures 3a-c) . Similar results were obtained by using confocal scanning (Supplementary Figure 5) . The ability of GPI to increase telomere damage induced by RHPS4 is strictly associated with its property to reduce the formation of poly-ADP ribose polymers (Supplementary Figure 6 ). The analysis of the telomere status by fluorescence in situ hybridization on metaphase spreads revealed that PARP inhibition synergized with RHPS4 in increasing chromosome aberrations, with a mean of 15.1±0.8 damaged telomeres in GPI/RHPS4-vs 5.0 ± 0.7 in RHPS4-treated metaphases (Figures 3d and e) . Furthermore, treatment with RHPS4 in the presence of the PARP inhibitor induced the appearance of terminal loss or deletion, revealed as a decreased intensity or a lack of telomere signal on one or both sister chromatids, dicentric chromosomes and telomeres with double minute chromosomes (Figures 3d and e) . Nonetheless, these results suggest that cells treated with RHPS4 in the presence of PARP inhibitor could not efficiently repair DNA strand breakages at telomeres. Consistent with this hypothesis, we found that the inhibition of PARP markedly prevented the activation of both phospho-ATM and MRE11 at the telomeric region upon RHPS4 treatment (Figures 3f-h ). Thus, we concluded that PARP activation is required to both signal and repair telomeres damaged by RHPS4.
On the basis of these results, the biological relevance of PARP inhibition has been evaluated on two different human colon carcinoma cell lines. Although GPI per se did not affect cell cycle and survival both in HT29 and HCT116 lines, it was able to increase RHPS4-induced perturbation of cell cycle phases, leading to the appearance of a population with a sub-G 1 DNA content ( Figure 4A ). Consistently, exposure to GPI and RHPS4 in combination was effective in increasing the cytotoxic activity of RHPS4, with the surviving fraction being reduced by about 50% in the GPI-RHPS4 treatment compared with RHPS4 alone ( Figure 4B ). Interestingly, the combined treatment impacted the viability of cells that utilize the ALT mechanism (Supplementary Figure  7) . Of note, the sequence of administering the two drugs is critical in determining the chemo-sensitizer activity of the PARP inhibitor to RHPS4, because the opposite sequence of treatment did not produce an increase in RHPS4 cytotoxicity (Figures 4a and b) .
PARP inhibition increases the antitumoral activity of RHPS4-based therapy
On the basis of the in vitro results, we subsequently evaluated the efficacy of the GPI/RHPS4 combination in vivo on tumors xenografted in immunosuppressed mice, by starting treatment on day 4 after cell injection, when a tumor mass was evident at approximately 300 mg. The treatment of mice with GPI alone did not reduce the growth of HT29 xenografts (Table 1) , thus confirming the in vitro data and our results already published (Tentori et al., 2006 and this paper) . When the HT29 tumor-bearing mice were treated with RHPS4, an inhibition of about 30% of the tumor weight was observed and the pre-treatment with GPI was able to significantly (Po0.01) reduce the growth of tumors compared with RHPS4 alone up to about 50% (Figure 5a , left panel and Table 1 ). In addition, the combination treatment improved the survival of mice up to 45% (Po0.001) (Figure 5a , right panel and Table 1 ). Finally, in the attempt to search for more effective anticancer therapy, we tested whether adding the TOPOI inhibitor could increase the therapeutic efficacy of the GPI/RHPS4 combination. This multi-component therapeutic strategy is based on previous data showing synergistic interaction between RHPS4 and CPT as well as CPT and PARP inhibitors (Tentori et al., 2006; Leonetti et al., 2008) , and on data reported in this paper describing the activation of PARP at telomeres upon CPT treatment. The pre-treatment with GPI increased the tumor weight inhibition elicited by either RHPS4 or irinotecan (Figure 5a , left panel and Table 1 ). When GPI was administered before each irinotecan or RHPS4 treatment, a more relevant antitumor efficacy was observed, reaching a 90% tumor weight inhibition (Po0.001). These results elicited a marked delay of tumor growth (23 days) and, more interestingly, showed a complete regression of the tumor in all the treated mice (8/8) (Figure 5a , left panel and Table 1 ). After 2 weeks the tumor recurred in three out of eight mice treated with this combination, but these animals showed a marked increase of survival compared with control (P ¼ 0.009) and all the other treated groups (P ¼ 0.01) (Figure 5a , right panel and Table 1 ). The remaining five out of eight mice showed no relapse of tumor growth and they were considered cured after being administered the triple combination (Table 1) , as tumors were no longer observed from the histological analysis performed on mice 6 months after the end of treatment. These results were also confirmed by bioluminescence imaging analysis. As reported in Figure 5b , tumor progression was observed in mice treated with GPI/ irinotecan combination, whereas tumor stabilization and, more relevant, tumor disappearance were found in mice administered with the multi-component therapy.
The high therapeutic efficacy of this strategy has also been demonstrated on mice bearing HCT116 colon carcinoma tumors. Although the response of this tumor to the triple combination was less pronounced, the injection of the second cycle of treatment produced a complete regression of the tumor and eventually cured three out of eight mice ( Figure 6A and Supplementary  Table 1 ). More importantly, experiments performed at an advanced stage of HT29 tumor growth (when a tumor mass of approximately 500 mg was evident, which PARP inhibition increases the efficacy of telomere-based therapy E Salvati et al was almost twice that in previous experiments) revealed (i) that the GPI/irinotecan/RHPS4 combination was still highly effective in inhibiting the progression of tumors with complete regression in two out of eight mice; (ii) a significant increase of mice survival (132%, Po0.001); and (iii) one out of eight mice cured ( Figure 6B and Supplementary Table II) . The pharmacodynamic monitoring for effects in HT29 xenograft tissues showed that the highest therapeutic efficacy of the GPI/irinotecan/ RHPS4 combination did not result from the inhibition of angiogenesis and only a slight increase in the percentage of apoptotic cells was found in the triple combination compared with the groups treated with both GPI/RHPS4 and irinotecan/RHPS4 schedules (4.6 ± 0.7 vs 3.2 ± 0.3 or vs 3.6 ± 1.3) (Figures 6c and  d) . Interestingly, GPI/irinotecan/RHPS4 combination markedly enhanced the percentage of gH2AX-positive cells (19.5 ± 4.5 vs 4.2 ± 1.8 or vs 11.8 ± 0.9), as well as the immunostaining intensity of the positive cells. Consistent with these results, the triple combination significantly induced the presence of pro-metaphase figures, which appeared gH2AX positive (38.2 ± 3.2 vs 3.3±1.5 or vs 22.3±7.5), indicating chromosome damage (Figures 6b-d) . Overall, our results clearly demonstrate the high therapeutic efficacy of this multi-component strategy even at a late stage of tumor growth that closely mimics the clinical setting.
Discussion
New anti-telomere strategies represent important goals for developing selective cancer therapies because most human cancer cells acquire the ability to activate telomerase and possess altered telomeres as compared with their normal counterpart. For instance, G4 ligands are promising compounds because they limit the proliferation of cancer cells by both short-term (telomere uncapping) and long-term (telomerase inhibition) effects. RHPS4 is one of the most selective G4 ligands with anticancer activity both as a single agent and in combination with CPTs in pre-clinical models of solid tumors (Salvati et al., 2007; Leonetti et al., 2008) . This agent, behind its classical telomerase-inhibitory properties, impairs fork progression and/or telomere processing, resulting in telomere dysfunction and activation of an ATR/ATM signaling pathway (Rizzo et al., 2009) . Overall, these studies show us how an agent of this novel class may be used clinically in combination with chemotherapeutic agents and warrant further investigations.
In this study, we found that uncapped telomeres, generated by treatment with the G4 ligand RHPS4, induce the specific activation of PARP1 at the telomeres, as well as the formation of several PARs that co-localize with the telomeric protein TRF1, which are inhibited by a selective PARP inhibitor. In addition, we showed that PARP1, but not PARP2, is activated and induces poly-ADP ribosylation upon RHPS4 treatment. In agreement with this separate role of PARP1 and PARP2 at telomeres upon RHPS4 treatment, a previous study demonstrated that, although both PARP members bind TRF2, they have different telomeric roles in telomerasepositive and ALT cells (Dantzer et al., 2004) . However, we cannot exclude that the different roles of PARP1 and PARP2 could be cell-and/or drug-type dependent. The activation of PARP1 upon G4-induced telomere damage is consistent with data showing that PARP1 localizes sporadically at undamaged telomeres, but preferentially at telomeres upon induction of DNA damage or loss of telomeric DNA (Gomez et al., 2006 , and this paper). However, although nearly all the PAR spots induced by RHPS4 localized to telomeres, the poly-ADP ribosylation as well as PARP1 signals activated by other types of DNA-damaging agents are mostly detected at the non-telomeric regions (Gomez et al., 2006 , and this paper).
Amazingly, poly-ADP ribosylation does not occur at uncapped telomeres stemming from loss of function of the telomere capping proteins TRF2 or POT1. The recruitment of PARP1 and PARP2 to the telomeres is expected to be TRF2 dependent, because PARP1 associates with TRF2 and PARP1/TRF2 interaction, helping PARP1 localize to sites of DNA strand breakages at telomeres. Therefore, a reduced amount of TRF2 can prevent PARP recruitment and activation at telomeres, providing an explanation for the lack of poly-ADP ribosylation upon TRF2 dysfunction. It also has been reported that the poly-ADP ribosylation of telomeric proteins inhibits their telomeric DNA-binding activity (Gomez et al., 2006; Donigian and de Lange, 2007) . Therefore, as we previously reported that RHPS4 leads to POT1 dissociation, we can speculate that, upon RHPS4 treatment, PARP1 catalyzes the poly-ADP ribosylation of POT1, leading to its dissociation from telomeres.
We also found that, as RHPS4, CPT, a specific TOPO1 inhibitor, induces an important parylation at telomeres. The fact that both RHPS4 and CPT interfere PARP inhibition increases the efficacy of telomere-based therapy E Salvati et al with DNA replication, together with the known PARP activation by stalled replication forks, suggest that PARP1 activation is caused by telomere replication defects (Sugimura et al., 2008; Rizzo et al., 2009) .
The inhibition of PARP impairs activation of RHPS4-induced recruitment of phospho-ATM and MRE11, involved in checkpoint and repair by homologous recombination, and markedly increases telomere damages and chromosome abnormalities including end-to-end fusions of chromosome ends without detectable telomeric DNA. Thus, telomeric DNA strand breaks may activate and recruit PARP1 to help repair PARP inhibition increases the efficacy of telomere-based therapy E Salvati et al PARP inhibition increases the efficacy of telomere-based therapy E Salvati et al enzymes and/or act as the architecture of the damaged telomeres. The apparent contradiction regarding the inhibition of phosphorylation, activation of ATM by PARP1 inactivation and the concomitant increase of the phosphorylation of the ATM substrate H2AX can be justified by the fact that, as already reported in our previous paper, phosphorylation of H2AX is dependent on the ATR kinase (Salvati et al., 2007; Rizzo et al., 2009) . The biomedical relevance of PARP1 activation at telomeres upon RHPS4 treatment has also been highlighted in this paper by showing that the PARP inhibitor GPI 15427 enhanced RHPS4 antitumoral activity both in vitro and in xenograft models of human tumors. Of note, the administration sequence of the two drugs is crucial for the chemo-sensitizer activity of the PARP inhibitor, suggesting that PARP(s) have to be completely inhibited before drug damage.
We recently showed that the combination of RHPS4 with CPT also has a strong synergistic interaction in vitro on colon cancer lines and produced marked antitumor activity on xenografts (Leonetti et al., 2008) . Unfortunately, this combination failed to cure animals as no complete remissions were reported. Therefore, based on the observation that PARP inhibitors sensitize tumor cells to CPT as well as RHPS4 (Tentori et al., 2006 and this paper) , and in an attempt to search for a more effective anticancer therapy, we evaluated a multicomponent strategy based on the use of PARP and TOPOI inhibitors in combination with RHPS4. We found that the triple combination resulted in high therapeutic efficacy as revealed by a complete regression of tumors, accompanied by a significant increase of overall survival, and cure of about 50% of treated mice. Notably, this multi-component strategy remained effective even when it was started at a very late stage of tumor growth, demonstrating that inhibition of PARP could be a promising strategy to improve the response of solid tumors to G4-based therapy.
Overall, this study reveals an unexplored link between PARP1 and the G4 ligand RHPS4. The impact of these findings is broad for basic and biomedical research as well as for clinical applications: they reveal the key role of PARP1 in telomere damages that are selectively induced by RHPS4 and demonstrate the high efficacy of a multi-component strategy based on the use of PARP inhibitors in telomere-based therapies.
Materials and methods

Tumor cell lines
The human colorectal adenocarcinoma cell lines HT29 and HCT116 and transformed BJ fibroblasts expressing hTERT and SV40 early region (BJ-EHLT) were obtained and maintained as previously reported Leonetti et al., 2008) .
For RNA interference experiments, cells were transfected with 100 nM of siTRF2, siPOT1, siPARP1 or siPARP2 (Dharmacon Inc, Chicago, IL, USA) in 35-mm Petri dishes using lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA). siGFP was used as negative control for transfection (Dharmacon Inc).
Drugs
The following drugs were used: clinical-grade irinotecan (CAMPTO, Pfizer, Borgo S Michele, LT, Italy), pentacyclic acridine RHPS4 (Heald et al., 2002) , NU1025 used at a concentration of 200 mM (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and orally bioavailable PARP inhibitor GPI 15427 used at a concentration of 2 mM (Eisai, Baltimore, MD, USA). Drugs were freshly prepared before each experiment.
Antibodies
The following primary antibodies were used: mAb to poly-ADP ribose polymers clone10H; mAb to PARP1 (clone C2-10) and pAb to PARP2 (Alexis, Lausen, Switzerland); mAb to gH2AX (Upstate, Lake Placid, NY, USA); mAb and pAb to TRF1; pAb to pospho-ATM (Ser1981) (Abcam, Cambridge, UK); pAb to MRE11 (Imgenex, San Diego, CA, USA); and Nude mice were implanted i.m. with tumor cells at 3 Â 10 6 cells/mouse and treated with the different schedules as from day 4 after tumor implant when a tumor mass of about 300 mg was evident in mice. Mice were treated with RHPS4 i.v. at 10 mg/kg/day for 15 consecutive days and Irinotecan i.p. at 15 mg/kg/day for 5 consecutive days alone or in combination. GPI was given p.o. at 40 mg/kg/day 1 h before each RHPS4 or Irinotecan administration. b A complete tumor regression was considered when no tumors were evident by palpability in treated mice. c Median survival time of the control group was 25 days (22-28). Survival of mice treated with schedule f is significantly different from control group (P ¼ 0.009), from schedule a (P ¼ 0.013), from schedule c and d (P ¼ 0.011) and from schedule b and e (P ¼ 0.01). d Survived mice were killed 12 months after the end of treatments and histological analysis was performed on leg muscle and on the major organs to validate the complete cure.
Figure 5 PARP inhibition increases antitumoral activity of RHPS4-based therapy. Nude mice were implanted intramuscularly with HT29 tumor cells at 3 Â 10 6 cells/mouse and treated with RHPS4 intravenously at 10 mg/kg/day for 15 consecutive days and Irinotecan intraperitoneally at 15 mg/kg/day for 5 consecutive days alone or in combination. GPI was given per os at 40 mg/kg/day 1 h before each RHPS4 or Irinotecan administration. Tumor-bearing mice were treated with the different schedules when a tumor mass of about 300 mg was evident in mice. Height mouse/group were employed and therapeutic efficacy was evaluated as reported in PARP inhibition increases the efficacy of telomere-based therapy E Salvati et al Figure 6 Treatment with GPI/Irinotecan/RHPS4 combination increases damages in vivo. Nude mice were implanted intramuscularly with HCT116 and HT29 tumor cells at 3 Â 10 6 cells/mouse and treated with RHPS4 intravenously at 10 mg/kg/day for 15 consecutive days and Irinotecan intraperitoneally at 15 mg/kg/day for 5 consecutive days alone or in combination. GPI was given per os at 40 mg/ kg/day 1 h before each RHPS4 or Irinotecan administration. HCT116 (A) and HT29 (B) tumor-bearing mice were treated with the different schedules when a tumor mass of about 300 and 500 mg, respectively, was evident in mice. Height mouse/group were employed and therapeutic efficacy was evaluated as reported in Materials and methods. Mean PARP inhibition increases the efficacy of telomere-based therapy E Salvati et al mAb to CD31 (BD Pharmingen, San Diego, CA, USA). The following secondary antibodies were used: TRITC conjugated goat anti-rabbit and FITC conjugated goat anti-mouse (Jackson ImmunoResearch, West Grove, PA, USA).
Flow-cytometric analysis
The cell cycle analysis was performed by flow cytometry. Cells were washed in phosphate-buffered saline (PBS) and fixed in 70% ethanol in PBS. 1 Â 10 6 cells were centrifuged and resuspended in a staining solution (50 mg/ml PI, 75 KU/ml RNase A in PBS) for 30 min at room temperature in the dark and analyzed by flow cytometry using FACScalibur (BectonDickinson, San Jose, CA, USA). For each analysis 20 000 events were collected. Cell cycle distribution and percentage of apoptotic cells were analyzed using Cell Quest (Becton Dickinson) and ModFit LT (Verity Software House, Topsham, ME, USA).
Clonogenic assay
Cells were seeded at a density of 5 Â 10 4 cells/plate and exposed to RHPS4 after 24 h at a dose of 1 mM for 96 h or to GPI 15427 for 24 h. In the combination experiments the medium containing the first drug was removed and replaced with a fresh medium containing the second drug. The effect of the different treatments on the colony-forming ability of cells was analyzed as reported (Biroccio et al., 2002) .
Western blotting
Samples were collected and lysed in the Chaps Buffer for 30 min in ice and the western blot and detection were performed as reported (Biroccio et al., 2002) . To check the amount of proteins transferred to nitrocellulose membrane, b-actin was used as a control.
Analysis of PARP activity
For the analysis of PARP activity, cells (5 Â 10 5 cells), untreated or exposed to 0.5 mM RHPS4 for 12 or 24 h, were permeabilized with digitonin (0.1 mg/ml) in the presence of 0.25 mCi 3H-NAD þ (Perkin-Elmer, Milan, Italy) (Bakondi et al., 2002) .
Immunofluorescence Cells were fixed in 2% formaldehyde and permeabilized in 0.25% Triton X-100 in PBS for 5 min at room temperature or in methanol for 10 min at À201, then rinsed in PBS. For immunolabeling, cells were incubated with primary antibody at room temperature for 2 h, then washed in PBS and incubated with the secondary antibodies.
For metaphase chromosome preparation cells were treated with demecolcine (Sigma, Milan, Italy) 0.1 mg/ml for 4 h and then harvested and washed in 75 mM KCl for 5 min at 37 1C. After centrifugation cells were fixed in MetOH/acetic acid 3:1 overnight and then spread on slides. Hybridization with rhodamine-coupled PNA was performed as described by Lenain et al. (2006) . Images of the metaphases were captured with an Â 100 objective. Fluorescent signals were recorded by using a Leica DMIRE2 microscope equipped with a Leica DFC 350FX camera and elaborated by a Leica FW4000 deconvolution software (Leica, Solms, Germany). This system permits to focus single planes inside the cell generating 3D high-resolution images. For each nucleus a single plane was analyzed and at least 50 nuclei per sample were scored.
Analysis of in vivo therapeutic efficacy CD-1 male nude (nu/nu) mice, 6-8 weeks old and weighing 22-24 g, were purchased from Charles River Laboratories (Calco, Italy). All procedures involving animals and their care were conducted as described (Salvati et al., 2007) . Treatments were as follows: RHPS4 was given intravenously at 10 mg/kg/ day for 15 consecutive days; irinotecan was administered intraperitoneally at 15 mg/kg/day for 5 consecutive days; GPI 15427 was administered per os at 40 mg/kg/day. In the combination experiments, GPI 15427 was given 1 h before each RHPS4 or irinotecan administration (Tentori et al., 2006; Leonetti et al., 2008) . To evaluate antitumor efficacy of the different treatments, HT29 or HCT116 cells were implanted at 3 Â 10 6 cells/mouse and drugs were injected when a tumor mass of approximately 300 or 500 mg was evident in the mice. Antitumor efficacy of treatments was assessed by the following end points: (a) percent tumor weight inhibition (Geran et al., 1972) ; (b) tumor growth delay, evaluated as TÀC, where T and C are the median times for treated and control tumors, respectively, to achieve equivalent size; (c) complete tumor regression, defined as tumor disappearance, as evaluated by palpability, lasting for at least 10 days during or after treatment period; (d) increase of mice survival by euthanizing the animals, for ethical reasons, when the tumors reached 3 g in weight; (e) cure defined as no evidence of disease at least for 6 months after the end of treatment.
Bioluminescence imaging analysis HT29 cells were stably transfected with the PGL2 vector containing the firefly luciferase gene under control of the SV promoter (Promega, Madison, WI, USA). Human xenografts were imaged using the IVIS imaging system 200 series (Caliper Life Sciences, Hopkinton, MA, USA). Briefly, mice were anesthetized with a combination of tiletamine-zolazepam (Telazol, Virbac, Carros, France) and xylazine (xylazine/ Rompun BAYER) given intramuscularly at 2 mg/kg. Then mice were injected intraperitoneally with 150 mg/kg D-luciferin (Caliper Life Sciences), and imaged in the supine position 10-15 min after luciferin injection. Data were acquired and analyzed using the living image software version 3.0 (Caliper Life Sciences).
Immunohistochemical analyses
Histological analysis and immunohistochemistry were performed as reported (Marcellini et al., 2006; Pisano et al., 2008) .
The number of tumor vessels per mm 2 was evaluated at Â 200 magnification. At least 10 fields for each case were randomly evaluated. Necrotic areas were excluded.
The detection of apoptosis was performed by TUNEL assay using In Situ Cell Death Detection Kit, POD (Roche Diagnostics Corp., Indianapolis, IN, USA) (Orlandi et al., 2008) . The number of apoptotic cells and their percentage were evaluated in at least 10 randomly selected fields at Â 40 magnification.
Statistical analysis
The Student's t-test (unpaired, two-tailed) was used for comparing statistical differences. Survival curves of mice were generated by Kaplan-Maier product-limit estimate, and statistical differences between the various groups were evaluated by log-rank analysis with Yates correction (software Primer of Biostatistics, McGraw-Hill, New York, NY, USA). Differences were considered statistically significant when Po0.05.
